Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Colorado Anschutz

Sites in Aurora, CO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1007
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Colorado Anschutz, Aurora, CO
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Colorado Anschutz, Aurora, CO. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 853–864 of 1,007 matching trials with a site at University of Colorado Anschutz, Aurora, CO.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Induction FLOT With CROSS CRT for Esophageal Cancer

NCT04028167
Site status not listed — check the official record
View directory record Official record
Conditions
Adenocarcinoma Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Interventions
Sequential FLOT followed by chemoradiation
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Nov 4, 2026, 6:16 AM EST
Recruiting No phase listed Observational

Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs

NCT02493478
Status at this site: Recruiting
View directory record Official record
Conditions
Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
150,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Nov 4, 2026, 6:16 AM EST
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

NCT06422923
Status at this site: Recruiting
View directory record Official record
Conditions
Epilepsy, Temporal Lobe
Interventions
NRTX-1001
Biological
Lead sponsor
Neurona Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Nov 4, 2026, 6:16 AM EST
Active, not recruiting Phase 3 Interventional Results available

RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

NCT00956007
Site status not listed — check the official record
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, intensity-modulated radiation therapy
Biological · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2029
U.S. locations
250
States / cities
Birmingham, Alabama • Tucson, Arizona • Auburn, California + 191 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Nov 4, 2026, 6:16 AM EST
Active, not recruiting Phase 2 Interventional Results available

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

NCT01196936
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen Citrate, Placebo, Digital mammography, immunohistochemistry staining method, pharmacological study, laboratory biomarker analysis, protein expression analysis, pharmacogenomic studies, questionnaire administration, Fine needle aspiration, Quality of Life Assessment
Drug · Procedure · Other + 1 more
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Nov 4, 2026, 6:16 AM EST
Active, not recruiting Phase 3 Interventional Results available

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00565851
Site status not listed — check the official record
View directory record Official record
Conditions
Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma
Interventions
Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2028
U.S. locations
680
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 421 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Nov 4, 2026, 6:16 AM EST
Active, not recruiting Not applicable Interventional Results available

LIFE-BTK Randomized Controlled Trial

NCT04227899
Site status not listed — check the official record
View directory record Official record
Conditions
Critical Limb Ischemia (CLI)
Interventions
Esprit BTK Device, Percutaneous Transluminal Angioplasty (PTA) Device
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
43
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Deer Park, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Nov 4, 2026, 6:16 AM EST
Active, not recruiting Not applicable Interventional

Time and Nutrient-Dependent Effects of Aerobic Exercise on Metabolism in Adults (TANDEM Study)

NCT06311487
Site status not listed — check the official record
View directory record Official record
Conditions
Overweight and Obesity, Healthy
Interventions
Fasted-AM, Fed-AM, Fasted-PM, Fed-PM
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Nov 4, 2026, 6:16 AM EST
Active, not recruiting Phase 3 Interventional

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

NCT02201992
Site status not listed — check the official record
View directory record Official record
Conditions
ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions
Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2036
U.S. locations
1613
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Nov 4, 2026, 6:16 AM EST
Recruiting No phase listed Observational

Von Willebrand Factor in Pregnancy (VIP) Study

NCT04146376
Status at this site: Recruiting
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
Use of a postpartum diary and additional blood draws., VWF replacement therapy with Wilate, Tranexamic acid
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
11
States / cities
Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Nov 4, 2026, 6:16 AM EST
Active, not recruiting Phase 2 Interventional Results available

Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers

NCT03347838
Site status not listed — check the official record
View directory record Official record
Conditions
Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer, History of Head and Neck Cancer
Interventions
Nivolumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Nov 4, 2026, 6:16 AM EST
Active, not recruiting Phase 3 Interventional Results available

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

NCT01844986
Site status not listed — check the official record
View directory record Official record
Conditions
Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy
Interventions
Olaparib 300mg tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
81
States / cities
Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Nov 4, 2026, 6:16 AM EST

About this University of Colorado Anschutz institution page

What this page lists
ClinicalTrials.gov records that list University of Colorado Anschutz in Aurora, CO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.